Disease · MONDO_0008599

trigeminal neuralgia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. trigeminal neuralgia. Diseases, record MONDO_0008599. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008599

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: trigeminal neuralgia; Open Targets
Open Targets ID: MONDO_0008599; Open Targets
Other names: Trifacial neuralgia, Trigeminal neuralgia (disorder), Trigeminal neuralgia NOS (disorder), Trigeminal neuralgia [no drugs here] (disorder), neuralgia of trigeminal nerve, trifocal neuralgia, trigeminal nerve neuralgia; Open Targets
Disease Ontology: DOID:12098; Disease Ontology
MeSH: D014277; MeSH
Orphanet: ORPHA:221091; Orphanet
Highest stage of its drugs: Approval, for 1 of its 27 drugs, from DailyMed; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CARBAMAZEPINE	CHEMBL108	Small molecule	Approval	DailyMed	18	7	7	Drugs and targets
VIXOTRIGINE	CHEMBL3544913	Small molecule	Phase 3	ClinicalTrials.gov	4	3	3	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
LAMOTRIGINE	CHEMBL741	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
BASIMGLURANT	CHEMBL3301626	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CYTIDINE	CHEMBL95606	Small molecule	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
DEXTROMETHORPHAN	CHEMBL52440	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ERENUMAB	CHEMBL3833329	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets86

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN9A	Sodium channel alpha subunit	8	Sodium channel alpha subunit blocker; Sodium channel protein type IX alpha subunit blocker	Approval	https://conductscience.org/library/genes/6335	Drugs and targets
SCN10A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6332	Drugs and targets
SCN8A	Sodium channel alpha subunit	7	Sodium channel alpha subunit blocker	Approval	https://conductscience.org/library/genes/6334	Drugs and targets

1 to 10 of 86

See all 86 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03941834	Trial for Treatment Refractory Trigeminal Neuralgia	Phase 2	65	2024-06-10	Trigeminal Neuralgia	RIMEGEPANT	Its record names the disease	ClinicalTrials.gov
NCT03865940	Efficacy of Guanfacine and Lidocaine Combination in Trigeminal Nerve Block for Pain Management in Trigeminal Neuropathy	Phase 2	37	2024-10-17	Trigeminal Neuralgia	GUANFACINE, LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT00203229	Research Study to Test Safety and Effectiveness of Investigational Drug in Patients With Trigeminal Neuralgia	Not applicable	20	2014-06-03	Trigeminal Neuralgia	LAMOTRIGINE	Its record names the disease	ClinicalTrials.gov
NCT02088632	Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia	Phase 2	6	2023-06-28	Trigeminal Neuralgia	INCOBOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT06410859	Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia	Phase 2	240		Trigeminal Neuralgia	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT06890897	Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia	Not applicable	174		Zoster; Herpes, Trigeminal Neuralgia (Etiology)	ESKETAMINE	Its record names the disease	ClinicalTrials.gov
NCT05217628	An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.	Phase 2/3	166		Trigeminal Neuralgia	BASIMGLURANT	Its record names the disease	ClinicalTrials.gov
NCT03331913	Botulinum Toxin for Trigeminal Neuralgia	Phase 3	150		Trigeminal Neuralgia	BOTULINUM TOXIN TYPE A	Its record names the disease	ClinicalTrials.gov
NCT06977932	The Alternative Effects of Electroacupuncture in the Treatment of Trigeminal Neuralgia	Not applicable	126		Trigeminal Neuralgia	CARBAMAZEPINE	Its record names the disease	ClinicalTrials.gov
NCT07252453	Comparison b/w Carbamazepine vs Oxcarbazepine in Treatment of Trigeminal Neuralgia	Not applicable	122		Trigeminal Neuralgia	CARBAMAZEPINE, OXCARBAZEPINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Lidocaine Alone vs Lidocaine + Guanfacine: deaths from any cause	0 of 36	0 of 28	64	NCT03865940	Trial comparisons
Lidocaine Alone vs Lidocaine + Guanfacine: serious adverse events	0 of 36	0 of 28	64	NCT03865940	Trial comparisons
DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo: Number of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase	0 of 28	0 of 29	57	NCT03941834	Trial comparisons
DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo: Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase	0 of 28	0 of 29	57	NCT03941834	Trial comparisons
DBT Phase: Pooled Rimegepant vs DBT Phase: Pooled Placebo: Number of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase	0 of 28	0 of 29	57	NCT03941834	Trial comparisons
Lamotrigine vs Placebo: serious adverse events	0 of 7	0 of 7	14	NCT00203229	Trial comparisons
Incobotulinumtoxina vs Placebo Comparator: deaths from any cause	0 of 3	0 of 3	6	NCT02088632	Trial comparisons
Incobotulinumtoxina vs Placebo Comparator: serious adverse events	0 of 3	0 of 3	6	NCT02088632	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31342515	RESULT	1	PubMed
42261299	DERIVED	1	PubMed
40326696	DERIVED	1	PubMed
35469443	DERIVED	1	PubMed
33249870	DERIVED	1	PubMed
30587219	DERIVED	1	PubMed
28216232	DERIVED	1	PubMed
27335883	DERIVED	1	PubMed
21621166	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008599

GET https://conductscience.org/api/diseases/v1/MONDO_0008599/drugs?page=2

API reference For AI assistants